414861-65-7Relevant articles and documents
Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors
Cullen, Matthew D.,Cheung, York-Fong,Houslay, Miles D.,Hartman, Tracy L.,Watson, Karen M.,Buckheit Jr., Robert W.,Pannecouque, Christophe,De Clercq, Erik,Cushman, Mark
, p. 1530 - 1533 (2008/09/19)
The alkenyldiarylmethanes (ADAMs) are currently being investigated as non-nucleoside HIV-1 reverse transcriptase inhibitors (NNRTIs) of potential value in the treatment of HIV infection and AIDS. During the course of these studies, a number of ADAM analog
Synthesis and biological evaluation of alkenyldiarylmethane HIV-I non-nucleoside reverse transcriptase inhibitors that possess increased hydrolytic stability
Cullen, Matthew D.,Deng, Bo-Liang,Hartman, Tracy L.,Watson, Karen M.,Buckheit Jr., Robert W.,Pannecouque, Christophe,De Clercq, Erik,Cushman, Mark
, p. 4854 - 4867 (2008/03/12)
Non-nucleoside inhibitors of HIV reverse transcriptase (NNRTIs), albeit not the mainstays of HIV/AIDS treatment, have become increasingly important in highly active antiretroviral therapy (HAART) due to their unique mechanism of action. Several years ago
Design, synthesis, anti-HIV activities, and metabolic stabilities of alkenyldiarylmethane (ADAM) non-nucleoside reverse transcriptase inhibitors
Silvestri, Maximilian A.,Nagarajan, Muthukaman,De Clercq, Erik,Pannecouque, Christophe,Cushman, Mark
, p. 3149 - 3162 (2007/10/03)
The alkenyldiarylmethane (ADAM) HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) are effective anti-HIV agents in cell culture. However, the potential clinical utility of the ADAMs is expected to be limited by the presence of methyl ester mo
